49 results about "Neuronal apoptosis" patented technology

The invention provides application of circular RNA circRNA-APP. Experiments prove that interference of circRNA-APP can significantly reduce expression of hippocampal small proinflammatory factors TNF-alpha and IL-1beta of APP / PS1 TG mice, inhibit generation of A beta and tau phosphorylation, promote expression of anti-inflammatory factors IL-10, inhibit neuronal apoptosis, improve neuronal synaptic structure plastic damage and improve the cognitive function of the APP / PS1 TG mice. The results show that the interference circRNA-APP can inhibit neuroinflammation, thereby inhibiting neuronal apoptosis and synaptic injury, and further improving the cognitive function of AD mice. Therefore, the circular RNA circRNA-APP can serve as a target spot to be used for preparing the medicine for treating or preventing the neurodegenerative diseases, and a new thought is provided for research and development of the medicine for preventing and treating the neurodegenerative diseases including the Alzheimer's disease.

Provided is a polypeptide which contains a polypeptide having at least 80%, 85%, 90%, 95%, or 99% identity to amino acid sequence MTYRPGYNPFG (SEQ ID NO: 41) or amino acid sequence AKGYYRPYGVPV (SEQ ID NO: 22), or a polypeptide having one or more amino acid substitutions, deletions and / or additions relative to the amino acid sequence as shown in SEQ ID NO: 41 or 22. The provided polypeptide can interfere with the binding of a Brag2 synaptic protein to the C terminus of an AMPA receptor, thereby inhibiting NMDA-mediated excessive endocytosis of an AMPA receptor and neuronal apoptosis, and playing a role in protecting neuronal cell activity. Therefore, the polypeptide has application prospects and potential development values as a drug for treating nervous system diseases such as strokes, depression, Alzheimer's disease and drug addiction.

The invention relates to the technical field of psychiatric pharmacology, discloses application of helicid in antidepressant drugs, and aims to solve the problems of large side effect, unstable curative effect, drug resistance and the like of existing antidepressant drugs. According to the medicine, through multiple mechanisms of activating a cAMP / PKA / CREB signal channel, promoting neuroplasticity, inhibiting neuronal apoptosis, relieving neuroinflammation and the like, the depressive symptom is remarkably improved. The preparation method comprises the steps of extraction and purification of helicid and preparation of the medicinal preparation. Animal experiments verify that the hilicidum-based antidepressant drug can effectively improve behavioral indexes of depression model rats, has low side effects, and does not have the problem of drug resistance. Compared with the traditional medicine, the medicine provided by the invention has the advantages that the treatment effect is improved, the adverse reaction is reduced, the application prospect is better, and a new medicine choice with a multi-target action mechanism is provided for the treatment of depression.

The present invention relates to the field of biomedicine technology, and discloses a use of melanin in the preparation of a drug for treating chronic ulcerative colitis and its associated depressive-like behavior. The present invention is the first to discover that melanin has the efficacy of treating chronic ulcerative colitis and its associated depressive-like behavior. MSPI can inhibit the LPS / TLR4 / NLRP3 / ASC / Caspase‑1 inflammatory signaling pathway, reduce oxidative stress, and restore the intestinal barrier, thereby improving UC symptoms. In addition, MSPI can also reduce glial cell activation, brain neuroinflammatory response and neuronal apoptosis, thereby reducing depressive-like behavior.

The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease, and belongs to the field of biopharmaceutical technology. The present invention provides the use of Yangxue Oral Liquid in the preparation of drugs for neuroprotection against Alzheimer's disease and / or Parkinson's disease. By verifying the effects of Yangxue Oral Liquid on the amyloid beta-induced neuronal apoptosis model, the cobalt chloride-induced SH‑SY5Y cell hypoxia model, and the LPS-induced SH‑SY5Y cell inflammation model, the results showed that Yangxue Oral Liquid has a neuroprotective effect against Alzheimer's disease and / or Parkinson's disease. Therefore, the application provided by the present invention provides a new means for neuroprotection against Alzheimer's disease and / or Parkinson's disease.

The invention discloses an edaravone homologue as well as a method and application thereof. The edaravone homologue has a structure shown in a formula (I), in the formula (I), R1 and R2 are substituent groups at any position on a benzene ring, and R1-R2 are the same or different and are independently selected from hydrogen or C1-C3 alkyl. Compared with edaravone, the edaravone homologue disclosed by the invention has the advantages that the oxidative stress level can be more effectively reduced, neuronal apoptosis is inhibited, and cerebral ischemia reperfusion injury is improved. # imgabs0 #

The invention belongs to the field of medicines, and discloses application of notoginsenoside R1 (NgR1) in preparation of a medicine for treating chemotherapy-induced peripheral neuropathy. The NgR1 can significantly increase the mechanical pain threshold of chemotherapy pain, reduce inflammatory cell infiltration in dorsal root ganglions and expression of inflammatory factors such as IL-6, TNF-alpha and IL-1beta, also can significantly improve microcirculation disturbance, reduce expression of CGRP and c-fos in spinal cords, reduce expression of Cleved caspase 3 (a marker of cell apoptosis) in the dorsal root ganglions, and significantly improve chemotherapy pain. Therefore, the chemotherapy-induced peripheral neuropathy is relieved in a multi-target manner. The NgR1 treats the CIPN through three ways of relieving inflammatory response, improving microcirculation disturbance and inhibiting neuronal apoptosis, the safe and effective treatment purpose is achieved, and a new strategy is provided for clinical treatment of the CIPN.

The invention discloses a neuronal apoptosis risk assessment system based on an oxidative stress signal axis. The neuronal apoptosis risk assessment system comprises the following steps: acquiring oxidative stress biomarker measurement data; calculating an oxidative stress signal axis activation index based on the oxidative stress biomarker measurement data; determining a neuronal apoptosis key factor expression level based on the oxidative stress signal axis activation index; calculating a neuronal apoptosis risk assessment value based on the neuronal apoptosis key factor expression level; and outputting the neuronal apoptosis risk assessment value. Compared with the prior art, the neuron apoptosis risk assessment method has the following advantages and effects: on the basis of integrated analysis of the oxidative stress signal axis multi-level biomarkers, through dynamic weight adjustment and activation index quantification, more accurate and systematic assessment of the neuron apoptosis risk is realized, and the reliability of risk assessment in non-diagnostic research is remarkably improved.

The invention relates to the technical field of medicine, and particularly discloses a specific small molecule medicine aiming at nervous system diseases and treatment application of the specific small molecule medicine aiming at the nervous system diseases, and the small molecule medicine is prepared from the following components: at least one group for selectively targeting a neurotransmitter receptor or nervous system related enzyme, or a peptide molecule or a derivative thereof for modification by a specific amino acid sequence; at least one biological activity for enhancing neuroplasticity, inhibiting nerve cell apoptosis, and slowing neurodegeneration; according to the invention, by designing a specific small molecule drug, a neurotransmitter receptor or nervous system related enzyme is accurately targeted, and nervous system signal transmission is adjusted; by targeting a specific neurotransmitter receptor or enzyme, the medicine can directly adjust the function of a lesion area without interfering with other irrelevant physiological processes; and the action efficiency of the medicine in the nervous system can be remarkably improved through precise targeting, so that the medicine can play a role at a relatively low dosage, and the side effects of the medicine are reduced.

The invention relates to the technical field of virology, in particular to application of idebenone in preparation of medicines for treating prion diseases. It is found that idebenone can effectively relieve oxidative damage and neuronal apoptosis caused by prion viruses, further plays a role in relieving and treating the prion viruses and has the potential of serving as a medicine for relieving or treating the prion viruses; a further mechanism research shows that idebenone relieves oxidative damage and neuronal apoptosis caused by prion viruses by activating SIRT3-SOD2. The new application of idebenone provided by the invention provides a new medicine and a new method for treating prion.

The invention provides an engineered TAT and RVG dual-targeting peptide modified exosome loaded microRNA inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the engineered TAT and RVG peptide exosome, the exosome is extracted from a supernatant of an MSC cell culture medium, the DiR-labeled exosome, FITC-labeled CP05-TAT peptide and 5-TAMRA-labeled CP05-RVG peptide are mixed and incubated together, the TAT and RVG dual-targeting peptide modified exosome is obtained, a miR-15b-5p inhibitor is loaded through ultrasound, and Exo-TATamp loaded with the miR-15b-5p inhibitor is prepared; the TAT and the RVG are used for co-modifying the MSC-EXOs, so that blood-brain barrier penetration and neuronal targeting can be remarkably enhanced, the delivery effect of a microRNA-15b-5p inhibitor is enhanced, and the injury induced by cerebral ischemia reperfusion is relieved by inhibiting neuronal apoptosis.

The invention discloses a pyrazolone compound as well as a preparation method and application thereof. The pyrazolone compound has a structure as shown in a formula (I), in the formula (I), R1 and R2 are substituent groups at any position on a benzene ring, and R1-R2 are the same or different and are independently selected from hydrogen or C1-C6 alkyl. Compared with 3-methyl-1-phenyl-2-pyrazoline-5-ketone (EDA), the pyrazolone compound disclosed by the invention can be used for more effectively inhibiting oxidative stress, inhibiting neuronal apoptosis and improving cerebral ischemia reperfusion injury. # imgabs0 #

The invention discloses an application of a tendulin fragment in preparation of a medicine for treating Tau proteopathy, and belongs to the technical field of biology. The amino acid sequence of the tenascin fragment is shown as SEQ ID NO.1. The tenascin fragment can inhibit Tau protein aggregation, inhibit cell oxidative stress induced by K18PFFs and improve neuronal apoptosis and synaptic dysfunction induced by K18PFFs, and can be used for preparing a Tau protein aggregation inhibitor and a medicine for treating Tau proteopathy.

This invention discloses a wearable targeted static magnetic field device and its usage method for early intervention in Alzheimer's disease, belonging to the field of physical therapy equipment technology. The device consists of a permanent magnet array, a metal shield, a magnet support device, and a support shell suitable for wearing on the head. The device generates a constant static magnetic field spatial distribution with multiple focal points and a specific gradient within the wearer's skull through the arranged permanent magnet array. The characteristic parameters of this distribution include: multiple local intensity peaks of 10-50 mT and a spatial gradient of 0.5-5 T / m. As an intervention method, the static magnetic field can significantly inhibit Tau protein LLPS, reduce neuronal apoptosis, and improve the patient's cognitive function. This invention is a soft, elastic, wearable device that provides a novel, precisely targeted, and easy-to-use physical therapy solution for AD.

The invention belongs to the technical field of drug delivery systems, and discloses multifunctional microalgae hydrogel as well as a preparation method and application thereof. According to the multifunctional microalgae hydrogel, natural components are taken as carriers, efficient release of drugs at the far end of the intestinal tract is achieved through pH and an intestinal flora enzyme response mechanism, the retention time of the far end of the intestinal tract is remarkably prolonged in combination with the adhesion characteristic, and the time-space distribution of the drugs is monitored in real time by supporting a fluorescent tracing technology. Meanwhile, by precisely regulating and controlling the homeostasis of intestinal flora, the intestinal barrier and the blood brain barrier are repaired, neuroinflammation, neuronal apoptosis and A beta deposition are remarkably improved, and cognitive impairment is reversed. The technical bottlenecks of poor targeting property and low bioavailability of a traditional oral preparation are broken through, a safe and efficient novel drug delivery strategy is provided for intervening neurodegenerative diseases based on the intestine-brain axis, and the preparation has remarkable clinical transformation potential and application value.

The invention provides a drug-loaded nano-microsphere for spinal cord injury recovery and application thereof, and relates to the technical field of biomedicine, the technical key point is that the drug-loaded nano-microsphere is provided, the drug-loaded nano-microsphere is characterized in that the drug-loaded nano-microsphere is prepared by an emulsified solvent evaporation method, a polymer and a drug are dissolved in an organic solvent, and the polymer and the drug are mixed uniformly to obtain a drug-loaded nano-microsphere solution; then emulsifying into a water phase, and finally, volatilizing an organic solvent to form microspheres; polyethylene glycol and a targeting ligand are added on the surface of a modified nano-microsphere, and the drug inhibits the SOCS3 / STAT pathway in a targeting manner. According to the research, a GM1-PLGA-PEG (at) FPR2 nano delivery system with a spinal cord targeting function is constructed, the system is good in slow release performance and high in biocompatibility, and neuronal apoptosis after H2O2 stimulation is effectively reduced. The drug-loaded nano-microspheres are used for simulating treatment of spinal cord injury, so that various movement functions and spinal cord health of rats with spinal cord injury can be improved, and the injured spinal cord can be targeted to promote neural restoration. The GM < 1 >-PLGA-PEG microspheres do not show strong liver retention, and show good biological safety in various tissues.

The invention discloses a medicine for preventing cerebral ischemia reperfusion injury and a preparation method thereof, and relates to the technical field of cerebral ischemia reperfusion injury prevention. Comprising the following steps: S1, screening fresh raw material ginkgo leaves to remove damaged incomplete defective products with insect pest traces, and crushing the ginkgo leaves into powder by using a crusher; sa1, after the kudzu vine roots are cut into blocks and boiled, drying and smashing are conducted, then 95% ethyl alcohol is mixed into the kudzu vine root powder according to the proportion of 1: 2, and then heating is conducted for two hours at the temperature of 75 DEG C; the ginkgo biloba extract contains ginkgo flavone, bilobalide and other active ingredients capable of preventing cerebral ischemia reperfusion injury, bilobalide can reduce neuronal apoptosis and necrosis in the cerebral ischemia reperfusion process, puerarin can also play a role in scavenging free radicals and inhibiting oxidation reaction, and can also play a role in preventing cerebral ischemia reperfusion injury. And the two are matched for use, so that a plurality of links of cerebral ischemia reperfusion which may cause injury to the brain can be covered, and brain tissues are more effectively prevented from being injured.

The present invention discloses the use of the TNFRSF1A inhibitor miR-3059-5p in the treatment of stroke. Examples of the present invention demonstrate that miR-3059-5p can inhibit neuronal apoptosis and parthanatos death induced by OGD / R by negatively regulating TNFRSF1A expression, thereby alleviating neuronal damage caused by OGD / R. Therefore, the research results of this invention provide a potential new drug for the clinical treatment of stroke.

The present invention discloses the use of likalin b and its preparation in the preparation of drugs for treating and / or alleviating cerebral hemorrhage. The present invention also discloses the use of mace isolignan and its preparation in the preparation of drugs for treating and / or alleviating cerebral hemorrhage. The likalin b, mace isolignan and its preparation can clearly improve the damage of neurons in the peripheral area of ​​cerebral hemorrhage in a collagenase-induced cerebral hemorrhage mouse model, inhibit the inflammatory response and neuronal apoptosis in the cerebral hemorrhage area and the surrounding brain area, and play a neuron protection role; at the overall animal level, it is manifested as alleviating the motor dysfunction and cognitive impairment of cerebral hemorrhage mice, increasing the number of neurons in the brain, and inhibiting the degeneration and death of neurons; therefore, likalin b, mace isolignan and its preparation can be used for the treatment of cerebral hemorrhage, and have the prospect of developing drugs.

The invention is applicable to the field of medicines, and particularly relates to a rhizoma cimicifugae-containing traditional Chinese medicine composition for treating Alzheimer's disease, which comprises the following components in parts by weight: 5-15 parts of rhizoma cimicifugae, 8-12 parts of ginseng, 10-15 parts of astragalus membranaceus, 6-10 parts of salvia miltiorrhiza, 4-8 parts of rhizoma acori graminei, 3-6 parts of polygala tenuifolia, 5-8 parts of spina date seed, 10-15 parts of poria cocos, 6-10 parts of radix ophiopogonis, 12-18 parts of oyster, 8-12 parts of concha haliotidis and 4-8 parts of gastrodia elata. The cimicifugae foetidae-containing traditional Chinese medicine composition for treating the Alzheimer's disease has the beneficial effects that the cognitive function is improved: the salvia miltiorrhiza, the rhizoma acori graminei and the polygala tenuifolia can promote cerebral blood perfusion, enhance synaptic plasticity and inhibit neuronal apoptosis; the rhizoma cimicifugae and the radix astragali are combined to improve brain microcirculation and reduce beta-amyloid protein aggregation, so that the learning and memory ability is remarkably improved.

Disclosed in the present invention are a tricyclic compound, a preparation method therefor and the use thereof. The tricyclic compound of the present invention are a tricyclic compound as shown in I', a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof. The tricyclic compound of the present invention is capable of protecting neurons, promoting repair of damaged neurons, inhibiting neuronal apoptosis, and slowing down AD cognitive decline, and have good pharmaceutical prospects.

Provided are molecules and compositions for eye-targeted gene therapy and methods of using the same. The eye-targeted gene therapy alleviates ischemic retinopathy by reducing pathologic neovascularization, gliosis and neuronal apoptosis.

The invention provides application of rosmarinic acid in treatment of cervical spondylotic myelopathy. Specifically, animal experiments and in-vitro cell experiments are carried out by constructing a rat cervical spondylotic myelopathy model, and it is verified that rosmarinic acid has a neuroprotective effect and can inhibit neuronal apoptosis under the conditions of ischemia and hypoxia. Experiments show that the rosmarinic acid can enhance mitochondrial autophagy by activating AMPK-TFEB and PINK1-PRKN signal pathways, so that neurons are protected from ischemia and hypoxia, and neuronal cell apoptosis is inhibited. Based on the invention, the rosmarinic acid or the derivative thereof can be used for preparing the medicine for treating cervical spondylotic myelopathy.

The invention discloses a new application of S-methyl-5-thioadenosine, and the S-methyl-5-thioadenosine can be used as a hepatic encephalopathy biomarker. The invention relates to application of S-methyl-5-thioadenosine, a pharmaceutically acceptable salt thereof and / or a prodrug thereof as an active ingredient in preparation of drugs for preventing and / or treating hepatic encephalopathy, MHE and neuroinflammation and application of S-methyl-5-thioadenosine, a pharmaceutically acceptable salt thereof and / or a prodrug thereof as an active ingredient in preparation of drugs for preventing and / or treating hepatic encephalopathy, MHE and neuroinflammation. The invention also relates to application in medicines for improving cognition. Clinical data, animal experiments and cell model researches find that MTA can effectively relieve neuroinflammatory response of MHE patients, inhibit neuronal apoptosis and improve cognition, so that learning and memory ability is improved, and the application prospect is wide.

The invention relates to the technical field of biological medicine and fundus disease treatment, in particular to application of Acbd3 in treatment of fundus diseases. In the retina of a fundus disease model mouse, the mRNA expression level and the protein expression level of Acbd3 are obviously increased relative to those of a control group. After the Acbd3 inhibitor is used, inflammatory response and neuronal apoptosis in the retina of the fundus disease model mouse are remarkably relieved, abnormal activation of Muller cells and microglial cells can be reduced, and the damaged blood-retina barrier can be repaired.

The invention discloses application of 4-methyleneglutamic acid in pharmacy, particularly relates to application of 4-methyleneglutamic acid in preparation of medicines for treating, improving or preventing cerebral apoplexy, and belongs to the technical field of medicines. Experimental results of the applicant show that when 4-methyleneglutamic acid is applied to preparation of the medicine for treating, improving or preventing cerebral apoplexy (especially hemorrhagic cerebral apoplexy), neuronal cell activity after cerebral hemorrhage can be improved, neuronal cell toxicity can be inhibited, neuronal apoptosis can be inhibited, and cerebral apoplexy can be inhibited. A new medicine choice is provided for preventing and / or treating the hemorrhagic stroke.

The present invention provides a milk casein hydrolyzate and its preparation method and application. The composition of the milk casein hydrolyzate of the present invention includes at least one of the peptide segment 1 with an amino acid sequence as shown in SEQ ID NO: 1, the peptide segment 2 with an amino acid sequence as shown in SEQ ID NO: 2, and the peptide segment 3 with an amino acid sequence as shown in SEQ ID NO: 3. The milk casein hydrolyzate has good neuronal protection and repair effects, can improve cholinergic neuron and dopaminergic neuron damage; can inhibit Aβ protein deposition, thereby alleviating neuronal synaptic disorders, neuronal apoptosis and brain damage caused by Aβ protein deposition; can improve cholinergic defects, thereby alleviating neurodevelopmental impairment, behavioral and motor disorders caused by cholinergic defects; can also repair damaged neurons in the hippocampus and hypothalamus, thereby maintaining a stable brain environment.

The invention provides application of XBP1 protein in preparation of a medicine for treating epilepsy, and relates to the technical field of biological medicine. In the pathophysiological process of epilepsy, X-box binding protein 1 (XBP1) serves as a key regulatory factor of endoplasmic reticulum stress and plays an important role, the XBP1 can regulate expression of endoplasmic reticulum stress related genes and inhibit neuronal apoptosis so as to influence the pathologic process of epilepsy, epilepsy is a chronic brain disease caused by multiple etiological factors, and the epilepsy is a chronic brain disease caused by multiple etiological factors. The invention develops an anti-epileptic drug based on a non-ionic channel as a target, and XBP1 is used as a beneficial supplement of the existing anti-epileptic drug and is beneficial to improving the effective rate of epileptic drug treatment on the whole.

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a medicine for treating cerebral arterial thrombosis, the medicine is prepared from the following raw materials in parts by weight: 10-15 parts of angelica sinensis, 6-10 parts of ligusticum wallichii, 10-15 parts of salvia miltiorrhiza, 6-10 parts of frankincense, 6-10 parts of myrrh, 3-6 parts of leech, 10-15 parts of centella asiatica and 10-15 parts of sculellaria barbata, experiments show that the medicine can effectively improve neurological functions; the cerebral infarction volume of the rat can be obviously reduced; in the aspect of brain tissue pathological damage, after the medicine is added for intervention, pathological changes such as nerve cell degeneration and necrosis occurring in a model group can be relieved to different degrees; under the condition of neuron apoptosis, the number of apoptotic cells of a model group is increased, and the medicine can reduce the number of apoptotic cells; in general, the medicine provided by the invention has a remarkable treatment effect on patients suffering from cerebral arterial thrombosis.

The invention provides a cryptotanshinone derivative, a preparation method thereof and application of the cryptotanshinone derivative in cerebral arterial thrombosis diseases. The cryptotanshinone derivative has a structure as shown in a formula I. Researches show that the compound DST-3 has good anti-stroke activity, can effectively reduce the cerebral infarction volume of a rat with ischemic stroke, reduce neuronal apoptosis and inhibit oxidative stress and inflammatory infiltration caused by ischemia reperfusion, and has a better comprehensive curative effect than cryptotanshinone. In addition, compared with the prior art, the DST-3 has better safety and oral bioavailability. The compound DST-3 has important application value in the aspect of developing drugs for treating cerebral apoplexy.